Iqbal Muhammad Waqas, Youssef Ramy F, Neisius Andreas, Kuntz Nicholas, Hanna Jonathan, Ferrandino Michael N, Preminger Glenn M, Lipkin Michael E
1 Division of Urologic Surgery, Duke University Medical Center , Durham, North Carolina.
2 Department of Urology, Johannes Gutenberg University Mainz , Mainz, Germany .
J Endourol. 2016 Jul;30(7):771-7. doi: 10.1089/end.2013.0257. Epub 2013 Nov 19.
Struvite stones have been associated with significant morbidity and mortality, yet there has not been a report on the medical management of struvite stones in almost 20 years. We report on the contemporary outcomes of the surgical and medical management of struvite stones in a contemporary series.
A retrospective review of patients who were treated with percutaneous nephrolithotomy (PCNL) for struvite stones at Duke University Medical Center between January 2005 and September 2012 identified a total of 75 patients. Of these, 43 patients had adequate follow-up and were included in this analysis. Stone activity, defined as either stone recurrence or stone-related events, and predictors of activity were evaluated after combined surgical and medical treatment.
The study included 43 patients with either pure (35%) or mixed (65%) struvite stones with a median age of 55±15 years (range 21-89 years). The stone-free rate after PCNL was 42%. Stone recurrence occurred in 23% of patients. Postoperatively, 30% of patients had a stone-related event, while 60% of residual stones remained stable with no growth after a median follow-up of 22 months (range 6-67 mos). Kidney function remained stable during follow-up. Independent predictors of stone activity included the presence of residual stones >0.4 cm(2), preoperative large stone burden (>10 cm(2)), and the presence of medical comorbidities (P<0.05).
Struvite stones can be managed safely with PCNL followed by medical therapy. The majority of patients with residual fragments demonstrated no evidence of stone growth on medical therapy. With careful follow-up and medical management, kidney function can be maintained and stone morbidity can be minimized. Initial large stone burden, residual stones after surgery, and associated medical comorbidities may have deleterious effect on stone recurrence or residual stone-related events.
鸟粪石结石与显著的发病率和死亡率相关,但近20年来尚未有关于鸟粪石结石药物治疗的报道。我们报告了当代一系列病例中鸟粪石结石手术和药物治疗的当代结果。
对2005年1月至2012年9月在杜克大学医学中心接受经皮肾镜取石术(PCNL)治疗鸟粪石结石的患者进行回顾性研究,共确定75例患者。其中,43例患者有充分的随访资料并纳入本分析。在联合手术和药物治疗后,评估结石活性(定义为结石复发或结石相关事件)及活性的预测因素。
该研究纳入43例单纯(35%)或混合(65%)鸟粪石结石患者,中位年龄为55±15岁(范围21 - 89岁)。PCNL术后结石清除率为42%。23%的患者出现结石复发。术后,30%的患者发生结石相关事件,而60%的残余结石在中位随访22个月(范围6 - 67个月)后保持稳定,无生长。随访期间肾功能保持稳定。结石活性的独立预测因素包括残余结石>0.4 cm²、术前结石负荷大(>10 cm²)以及存在内科合并症(P<0.05)。
鸟粪石结石可通过PCNL安全治疗,随后进行药物治疗。大多数有残余碎片的患者在药物治疗中未显示结石生长的证据。通过仔细的随访和药物管理,可以维持肾功能并将结石发病率降至最低。初始结石负荷大以及手术后的残余结石和相关内科合并症可能对结石复发或残余结石相关事件产生有害影响。